A.G. Kotelnikov1, V.I. Egorov2, 3, M.D. Ter-Ovanesov1, 4
1N.N. Blokhin National Medical Research Center of Oncology, Moscow
2Kazan State Medical University, Kazan
3Republican Clinical Oncology Dispensary named after Professor M.Z. Sigal, Kazan
4Nizhny Novgorod Regional Oncology Dispensary, Nizhny Novgorod
Egorov V.I. — PhD (Medicine), Associate Professor of the Department of Oncology, Radiation Therapy and Diagnostic Imaging, oncologist
49 Butlerov St., 420000 Kazan, Russian Federation, e-mail: drvasiliy21@gmail.com, ORCID ID: 0000-0002-6603-1390
Abstract. Metastatic pancreatic tumors account for approximately 2% of all pancreatic malignancies. In the structure of secondary pancreatic tumors, the proportion of kidney cancer metastases is 70%. Kidney cancer with metastases to the pancreas has a more favorable prognosis compared to patients with metastases in other organs, indicates certain biological features of this tumor subpopulation. Today, there is no unified approach to treating such patients. This review analyzes the results of studies on the biological characteristics of kidney cancer with metastases in the pancreas and the role of surgical and drug methods in its treatment. Based on the literature analysis, we can conclude that this clinical phenomenon has a unique biological profile, which determines a generally more favorable course. The role of drug therapy as an independent method of treatment is currently insufficiently studied. Despite the successes of immune and targeted therapy, the surgical method is still significant in view of the quite acceptable survival rates.
Key words: kidney cancer, metastasis of pancreas, targeted treatment, pancreatic resection, overall survival